Introduction
Interleukin-4 (IL-4), a cytokine produced primarily by activated CD4 + T lymphocytes, plays a central role in immune and inflammatory reactions. By inducing CD4 + T cell differentiation toward the Th2 phenotype and IgE isotype switching in B cells, 1,2 dysregulated IL-4 expression is thought to contribute to the development of allergic diseases including asthma. 3, 4 IL-4 also regulates the differentiation of multiple blood cell lineages. For example, in the presence of other growth factors (eg GM-CSF), IL-4 can inhibit the growth of myeloid progenitors (reviewed in Ref. 5 ). IL-4 also inhibits stem cell factor (SCF)-driven mast cell growth from cord blood cells, 6 which is probably mediated by inhibition of c-kit expression. 7 In contrast, IL-4 (together with other growth factors) can induce the differentiation of dendritic cells from peripheral blood, 8 and is required for the survival of resting T cells. 9 Finally, IL-4 can inhibit the growth of a variety of tumor IL-4 gene expression is tightly regulated at the level of transcription by multiple transcription factors that bind to ciselements in the upstream proximal promoter (Figure 1) . [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] A mast cell-specific intronic enhancer and a T cell-specific silencer in the 3Ј-untranslated region have also been described. 29, 30 Nuclear factor of activated T cell (NFAT) proteins are thought to enhance IL-4 gene expression by binding up to five potential sites in the promoter. 16, 18 These sites, termed P0 to P4, share a consensus sequence containing a core NFAT-binding motif: 5ЈGGAAAA3Ј.
Nucleotides surrounding the NFAT-binding core of individual P elements are highly divergent and support the binding of additional factors. As a result, each P element can be considered an individual transcriptional unit. The P1 element in particular plays a major role in promoting NFAT-dependent transactivation. 23, 25 In contrast, C/EBP (and not NFAT) proteins Leukemia transactivate the IL-4 promoter from the P4 element (or PRE-1). 31 Additionally, the human P3 element binds NF-Y more strongly than NFAT proteins due to a CCAAT box just downstream of the NFAT motif. 21 To dissect the contribution of each of the P elements in regulating IL-4 transcription, in this study we performed a detailed deletion analysis of the human IL-4 promoter using reporter constructs transiently transfected into Jurkat T lymphoblasts. This led to the identification of a novel negative regulatory element (NRE) overlapping the P2 NFAT site. NRE activity localized to the sequence −170 TTTCACAGGA −161 , which we term P2 NRE. Here we show that mutation of this sequence significantly enhances the activity of downstream activators in transient transfection assays. Using Jurkat nuclear extracts, we identified a candidate repressor factor that binds uniquely to P2 NRE and not to other human P elements in electrophoretic mobility shift assays (EMSA). This factor, termed Rep-1, has an apparent molecular mass of ෂ150 kDa, and appears to be distinct from other transcription factors previously shown to regulate IL-4 promoter transactivation.
Materials and methods

Plasmid construction
IL-4 promoter constructs were amplified from human genomic DNA using the polymerase chain reaction (PCR). 25-nucleotide (nt) 5Ј primers annealing −265, −225, −175, −145, −95, and −65 base pairs (bp) upstream from the transcription start site (tss) (according to Ref. 32) were used with a constant 25-nt 3Ј primer ending at position +65. Primers were designed to delete individual P elements, and incorporated restriction sites to facilitate subsequent ligation. PCR products were sequenced using the dideoxy method, and then ligated into the HindIII and XbaI sites of pCAT Basic (Promega, Madison, WI, USA). Mutations were introduced into the pCAT175 plasmid at 5 bp intervals using the following mutagenic 5Ј primers (mutations in small case): m1: CCAGTAAGCTTgagacTTTCA-CAGGAACATTTTAC; m2: CCAGTAAGCTTTCTGAgggacCAG-GAACATTTTACCTGTT; m3: CCAGTAAGCTTTCTGATTTCA gctcgACATTTTACCTGTTTG; m4: CCAGTAAGCTTTCTGAT TTCACAGGActcggTTACCTGTTTGTGAGGCAT.
Cell lines and transfections
Jurkat T cells (a gift of Dr Jack Strominger, Harvard University) were maintained in RPMI 1640 supplemented with 10% heatinactivated fetal calf serum (Life Technologies, Grand Island, NY, USA) and gentamycin. These cells constitutively express IL-4 mRNA (not shown). Cells of low passage number (Ͻ8 weeks) were used in transfection experiments. Cells (3 × 10 6 ) were transfected in duplicate using the lipofectamine method (Life Technologies) as follows: 5 h incubation, 2 g plasmid DNA, and 12 g lipofectamine, followed by 48 h culture in complete medium prior to harvest. The amount of plasmid DNA resulting in optimal CAT activity was determined for each reporter construct and centered around 2 g. Cells were stimulated with 1 m calcium ionophore (A23187; Calbiochem, La Jolla, CA, USA) or DMSO control for the last 18 h of culture followed by lysis by three freeze-thaw cycles. Reporter gene expression was determined either by measuring CAT activity using thin layer chromatography as described 33 ( Figure 2 ), or by assaying for CAT enzyme levels using a sensitive ELISA (Roche Molecular, Biochemicals, Indianapolis, IN, USA). Cell extracts were normalized for protein content using the Bradford method (Bio Rad) prior to assays for CAT gene expression.
Electrophoretic mobility shift assays (EMSAs)
The following 30-nt oligonucleotides and their complements were synthesized (mutations in small case): 5Ј-TCTGATTTCA-CAGGAACATTTTACCTGTTT-3Ј (P2 wt −175 to −146); 5Ј-gagacTTTCACAGGAACATTTTACCTGTTT-3Ј (m1); 5Ј-TCTGA gggacCAGGAACATTTTACCTGTTT-3Ј (m2); 5Ј-TCTGATTTCA gctcgACATTTTACCTGTTT-3Ј (m3); 5Ј-TCTGATTTCACAGGActcggTTACCTGTTT-3Ј (m4); 5Ј-ATCTGGTGTAACGAAA ATTTCCAATGTAAAC-3Ј (P1 −92 to −60). Nuclear extracts were obtained from 5 × 10 6 Jurkat cells using the method of Schreiber et al. 34 EMSAs were performed using 5 g nuclear protein, 0.8 g poly (dG-dC; Pharmacia Biotech, Piscataway, NJ, USA) and ␥
32
P end-labeled probe in a final volume of 10 l. Free probes and protein-DNA complexes were resolved by 5% polyacrylamide gel electrophoresis (PAGE) with 0.5× Tris-borate EDTA (TBE). In competition experiments, extracts were pre-incubated for 20 min at room temperature with 100-fold molar excess of the following commercially available consensus oligonucleotides: GRE: 5Ј-TCGACTGTA-CAGGATGTTCTAGCTACT-3Ј; AP1: 5Ј-CGCTTGATGAGT CAGCCGGAA-3Ј; mutAP1: 5Ј-CGCTTGATGAGTTGGCC GGAA-3Ј; AP2: 5Ј-GATCGAACTGACCGC CCGCGGCCCGT-3Ј; AP3: 5Ј-CTACTGGGACTTTCCACACATC-3Ј; CRE: 5Ј-AGAGATTGCCTGACGTCAGAGAGCTAG-3Ј; and mutCRE: 5Ј-AGAGATTGCCTGTGGTCAGAGAGC TAG-3Ј. In antibody experiments, extracts were incubated at room temperature with 1 l of the following anti-sera for 30 min after the addition of labeled probe: anti-NFATp (non-cross reactive with NFATc, courtesy of Dr A Rao, Harvard University), antiNFATc (7A6, courtesy of Dr G Crabtree, Stanford University), anti-c-Fos (4-10G, broadly cross-reactive with Fos family members) and anti-c-Jun (D, broadly cross-reactive with Jun family members, both from Santa Cruz Biotechnology, Santa Cruz, CA, USA).
UV cross-linking
Jurkat nuclear extracts (50 g) were incubated with a double stranded oligonucleotide encompassing the P2 oligonucleotide in a standard EMSA reaction using 4 g poly (dG-dC), followed by UV irradiation at 120 000 J/cm 2 for 20 min (UV Crosslinker 1000; Fisher Scientific, Chicago, IL, USA). The reaction mixture was subject to 5% PAGE with 0.5× TBE, and analyzed by autoradiography. The portion of the gel corresponding to Rep-1 (see was excised, DNA and protein were eluted, and then analyzed by sodium dodecyl sulfate (SDS)-PAGE using 5-6% gradient gels, followed by autoradiography of the fixed and dried gel. The molecular weight of Rep-1 was estimated by comparing the mobility of the observed band with radiolabeled molecular weight markers run in parallel, allowing for approximately 19 kDa due to the radiolabeled 30-bp oligonucleotide.
Figure 2
Detailed deletion analysis of the IL-4 promoter. The indicated constructs were transiently transfected into Jurkat T cells, and promoter activity was assayed after stimulation with calcium ionophore (1 m A23187 for 18 h) using thin-layer chromatography. The length of promoter fragments is indicated to the left of each construct (numbers refer to bp upstream from the tss), and the P elements are indicated by shaded boxes. Results from three experiments performed in duplicate are shown, and expressed as fold-induction over unstimulated reporter constructs. Identical amounts of plasmid DNA were used in each experiment, and two individual pCAT175 reporter constructs (pCAT175-1 and pCAT175-2) were used. Constitutive CAT activity varied between experiments (between 2 and 5% 14 C-chloramphenicol transacetylation).
Results
A negative regulatory element is located near the P2 element
IL-4 promoter reporter constructs were transiently transfected into Jurkat T cells and CAT activity was assayed after 18 h of cell activation. As we have previously shown, the IL-4 promoter is constitutively active in these cells, and maximal CAT activity was obtained using a calcium signal alone. 33 Figure  2 shows the results of three experiments using a series of deletion constructs in transient transfection assays. A striking finding was that constructs beginning 175 bp upstream from the tss (pCAT 175) were not inducible by a calcium signal, whereas the addition of 50 bp upstream (pCAT 225) or deletion of 30 bp (pCAT 145) restored inducibility. Constitutive activity of pCAT175 was also low. This result suggests that the region between bp −175 and −146 harbors a NRE that is able to suppress the activity of downstream activators, but is over-ridden by positive elements further upstream. Additional combinations of various agonists shown to regulate IL-4 transcription in different experimental systems (including PMA, PHA and 8Br-cAMP) also failed to induce pCAT 175 (not shown).
Several nuclear factors bind the P2 element in electrophoretic mobility shift assays
Detection of an NRE in this region of the human IL-4 promoter is a novel finding. This 30 bp stretch (between bp −175 and −146) contains the P2 NFAT site, which was originally identified based on sequence homology with an NFAT consensus sequence. 18 The mouse P2 element was found to bind NFAT and AP-1 proteins using nuclear extracts from EL-4 cells in EMSA. 18, 27 The human P2 element differs from its mouse counterpart, and other NFAT sites, within the 3Ј half of the recognition element:
−163 GGAACA −158 . Nonetheless, the human P2 element also supports the binding of NFAT and AP-1 using T cell nuclear extracts in EMSA. 35 We analyzed the ability of nuclear proteins isolated from Jurkat cells to interact with a 30-bp oligonucleotide spanning the −175 to −146 Leukemia region in EMSA. As shown in Figure 3 , six complexes formed on this oligonucleotide using nuclear extracts obtained from calcium ionophore activated cells. Using extracts from unstimulated cells, complex II (subsequently shown to contain NFATp, see Figure 4 ) formed with less intensity (not shown).
We next analyzed the sequence specificity of complex formation using a panel of related and unrelated competitor Characterization of the cellular factors that interact with the P2 oligonucleotide. Nuclear extracts from ionophore-stimulated Jurkat cells (1 m A23187, 2 h) were analyzed by EMSA. Six complexes (I to VI) formed. Competition analysis using 100-fold molar excess of unlabeled oligonucleotides is shown (lanes 3-8) . Complexes I and IV are not inhibited by any competitor, whereas complex II contains NFAT proteins (lane 3). oligonucleotides in EMSA. Complex II appeared to contain NFAT proteins since its formation was specifically inhibited using the high-affinity P1 NFAT site as competitor (Figure 3,  lane 3 ). This was confirmed using an AP3 oligonucleotide (lane 6), which also contains an NFAT-like sequence. 33 The formation of complex III was inhibited by oligonucleotides containing AP-1 and cAMP response element (CRE) consensus sequences. However, additional competition analysis using oligonucleotides with mutated AP-1 and CRE motifs also inhibited its formation (not shown), suggesting that this complex is due largely to non-specific DNA binding. Complex V was also competed for by the P1 NFAT oligonucleotide (lane 3). Notably, complexes I and IV were not competed for by any oligonucleotide tested.
Different pattern of complex formation on the P2 and P1 oligonucleotides
When we compared nuclear factor binding to the P2 oligonucleotide and to a similar length oligonucleotide containing the P1 sequence, we observed a strikingly different pattern of binding (Figure 4) . One major complex formed on the P1 oligonucleotide which contains predominantly NFATp (lane 7 and Ref. 33 ). As expected, formation of complex II on the P2 oligonucleotide was inhibited by anti-NFATp antibodies ( Figure 4, lane 3) . Interestingly, this complex was much less intense and migrated more quickly than the corresponding NFATp-immunoreactive complex on the P1 probe. We did not detect NFATc binding to either probe in these experiments (Figure 4, lanes 4 and 8) . Neither complex I nor complex IV formed on the P1 sequence. Complex III migrated with similar mobility as a band we had previously determined to be nonspecific on the related P1 oligonucleotide (n.s., Figure 4 ). Complex V (which occasionally resolved into two distinct bands) migrated with similar mobility as two high-mobility complexes (HMC-I and II) that formed on the P1 probe. The observation that the P1 probe in particular competed for this
Figure 4
A comparison of nuclear factor binding to the similar length oligonucleotide probes including the P2 (lanes 1-4) and P1 (lanes 5-8) elements. Experiments were carried out in parallel using identical reaction conditions and exposure times. As expected, complex II was inhibited by anti-serum specific for NFATp (lane 3), but unaffected by control serum (lane 2). The P1 NFATp-specific complex formed with much greater intensity and slower mobility than the corresponding complex on the P2 oligonucleotide (lanes 5-8) . Two high-mobility complexes (HMC-I and HMC-II) forming on this oligonucleotide have been previously described. 33 n.s. denotes non-specific.
complex ( Figure 3 , lane 3) suggests that complex V and HMC-I/II are related. In previous work, we found that HMC-I and HMC-II were not inhibited by a panel of unrelated oligonucleotide competitors, and they did not appear to be involved in the repression of the IL-4 promoter by RelA, which bound competitively with NFAT in the P1 region. 33 Since there are no other known negative regulatory elements within the P1 region, however, complex V is not a good candidate for a repressor factor.
Mutational analysis localizes the negative regulatory element
In order to better define the binding site of possible repressor factors, mutations were introduced into the pCAT175 plasmid (Figure 5a ) and the inducibility of mutated constructs was compared to that of wild-type pCAT175 and pCAT145. As shown in Figure 5 , pCAT175 m2 and m3 were significantly more active than wt (approximately five-fold). Thus, negative regulatory activity localized to the sequence
, which we term P2 NRE. Neither construct was as inducible as pCAT145, suggesting that repressor activity had not been fully abolished. We speculated that mutants m2 and m3 disrupted the binding of a transcriptional repressor and allowed greater inducibility of downstream enhancer elements. To test this hypothesis, we used mutated 30-bp P2 oligonucleotides in EMSA, and reasoned that a repressor factor would not readily bind the m2 and m3 oligonucleotides. As shown in Figure 6 , the formation of complex I was inhibited on both the m2 and m3 oligonucleotide probes. Note that a similar complex did not form on the P1 probe (Figure 4) , nor on similar length oligonucleotide probes including the other human P elements (Burke T and Georas S, unpublished observations). Thus, complex I is a good candidate for a repressor factor and will be subsequently referred to as Rep-1. In additional experiments using nuclear extracts obtained from peripheral blood T cells as well as from a pair of allergen-specific Th1 and Th2 clones (courtesy of Dr David Essayan, Johns Hopkins Asthma & Allergy Center) in EMSA, we found that a band of similar mobility as Rep-1 was equally expressed in all samples (not shown). Thus, Rep-1 expression does not appear to be restricted to the leukemic Jurkat cell line.
As expected, NFATp did not bind to the m3 and m4 oligonucleotides, consistent with the disruption of the core NFAT site by these mutations (Figure 6 ). Interestingly, NFATp bound with higher affinity to the m2 probe, suggesting that Rep-1 may act in part by competing for NFATp binding. Note, however, that pCAT175 m3, which binds neither NFATp nor Rep-1 (Figure 6 ), is also more active than wt suggesting that the major reason for the increased activity of m2 and m3 is diminished Rep-1 binding.
Rep-1 contains a single protein of apparent molecular mass of 150 kDa
In an attempt to better characterize Rep-1, we analyzed the composition of complex I by UV cross-linking and SDS-PAGE analysis. In these experiments, Jurkat nuclear extracts were
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Figure 6
Characterization of cellular factor binding to wild-type and mutated oligonucleotide probes. Nuclear extracts were obtained from ionophore-stimulated Jurkat cells as described and analyzed by EMSA. 30 bp wt and mutated probes labeled to similar specific activity were used with identical amounts of nuclear extracts and reaction conditions. Note that complex I does not bind the m2 and m3 oligonucleotide probes. This complex will be referred to as Rep-1 (see text). As expected, NFATp did not bind the m3 and m4 oligonucleotides.
incubated with the wild-type −175 to −146 bp oligonucleotide probe in a standard EMSA reaction followed by UV cross-linking, autoradiography and excision of the Rep-1 complex, and subsequent analysis by SDS-PAGE (see Methods). Figure 7 shows that Rep-1 appears to be made up of a single protein that migrates with an apparent molecular mass of approximately 150 kDa, after subtracting ෂ19 kDa attributed to the 30 bp oligonucleotide.
Figure 7
UV cross-linking and SDS-PAGE analysis. Rep-1 migrated as a single protein (arrow). The relative migration of radiolabeled molecular weight markers run in parallel are indicated.
Leukemia
Discussion
Expression of the interleukin-4 gene is tightly regulated at the level of gene transcription by multiple positively and negatively-acting transcription factors. Several factors involved in the cell type-specific regulation of IL-4 production have recently been identified. 22, [36] [37] [38] NFAT and C/EBP family members can enhance IL-4 transcription by interacting with multiple sites in the IL-4 promoter. 16, 18, 31 Relatively little is known, however, about factors that downregulate IL-4 transcription. Negative regulatory elements have been described in the proximal 300 bp of the IL-4 promoter and in the 3Ј-untranslated region. 19, 21, 30 For example, an NRE centered around bp −300 of the human IL-4 promoter was identified by Li-Weber et al. 19 In EMSA, this region bound two proteins: the T cellspecific Neg-1 and the ubiquitous Neg-2. IRF-2 has been suggested to downregulate the IL-4 promoter by binding an ISRElike sequence adjacent to the P3 element. 21 In transient cotransfection experiments, we showed that RelA/NFKB1 heterodimers and RelA homodimers inhibit the human IL-4 promoter by competing for NFAT binding to the P1 sequence. 33 HMGI/Y was recently shown to downregulate IL-4 transcription by a similar mechanism. 39 Additionally, we recently reported that Stat6 can downregulate the IL-4 promoter in Jurkat T cells, apparently by competing for NFAT binding to overlapping recognition elements. 40 In this report, we describe a novel negative regulatory element adjacent to the P2 NFAT site which we term P2 NRE.
It is worth noting that although the P2 NRE described in this report has not been previously characterized, two previous deletion analyses detected negative regulatory activity in this region of the mouse IL-4 promoter. 24, 25 In one study, an NRE between bp −213 and −115 was identified using CAT constructs transfected into EL-4 T cells. 25 In another study, deleting the 20 bp between −157 and −137 increased ionomycin and anti-CD3 inducibility of mouse IL-4 promoter constructs approximately two-fold in D10 cells. 24 Thus, negative regulatory activity in this region of the IL-4 promoter has now been detected in three different human and murine T cell lines. Because of differences in the species and scale of deletions, however, it is not definite that each of these findings was due to the P2 NRE.
Because the P2 NRE is flanked both upstream and downstream by additional enhancer elements, its negative regulatory activity only became apparent during a detailed promoter deletion analysis. In this respect, it appears to be related to other 'internal' NRE's that have been characterized in the proximal promoter regions of several cytokine genes, including those for IL-2, IL-3 GM-CSF, TNF-␣, IFN-␣ and IFN-␤. [41] [42] [43] [44] [45] [46] [47] Importantly, although these NREs are flanked by positive regulatory elements, they can significantly inhibit transcriptional activation of their respective genes. In additional experiments, we found that complex IV contained factors reactive with antibodies specific for the multifunctional transcription factor YinYang-1 (YY1), and we identified a binding site for this multifunctional factor just downstream of the P2 NRE (Georas S, unpublished observation). However, mutations that disrupted this element did not consistently affect activity of pCAT175 (m3 and m4 in Figure 5 ), suggesting that YY1 binding to this region does not play a major role in regulating activity of the minimal promoter.
Several lines of evidence support our contention that Rep-1 is the factor responsible for transcriptional repression from the P2 NRE. First, we have shown that formation of the lowmobility Rep-1 complex is inversely correlated with the activity of a 175-bp IL-4 promoter construct. Second, we did not detect a similar complex on oligonucleotide probes corresponding to the other human P elements in EMSA, suggesting that Rep-1 recognizes sequences unique to the P2 NRE. Rep-1 binding was not competed for by consensus sequences for many transcription factors (Figure 3 ), or by antibodies directed against NFAT, AP-1, Oct, Stat-6, or Bcl-6 proteins ( Figure 4 and data not shown). By UV cross-linking and SDS-PAGE analysis, we found that it migrates as a single protein with an apparent molecular mass of approximately 150 kDa. The identity of Rep-1, and the mechanism by which it inhibits transcriptional activation from downstream elements in the IL-4 promoter, are currently not known. Rep-1 might specifically antagonize the effects of NFATp on downstream elements since both basal and calcium ionophore-induced activity of pCAT175, both of which appear to be NFAT-dependent, are extremely low. In preliminary experiments, Rep-1 appeared to be equally expressed in nuclear extracts obtained from a pair of established allergen-specific Th1 and Th2 clones. However, defining the precise role of this factor in regulating differential cytokine gene expression in Th subsets awaits the determination of the molecular identity of Rep-1.
Further characterization of this and other factors that limit IL-4 promoter transactivation should enhance our understanding of IL-4 gene dysregulation in human diseases. For example, aberrant T cell production of IL-4 appears to favor the growth of certain B cell malignancies. 48, 49 In addition, emerging data suggest that Th2-dominant immune responses (ie characterized by IL-4 and IL-10 expression) are associated with worse outcomes in experimental lymphoma models. 50 Although the mechanisms responsible for dysregulated IL-4 production in these conditions are unknown, it is tempting to speculate that they involve primary defects in the expression and regulation of IL-4 promoter-specific transcription factors. Future studies of T cells isolated from human subjects with leukemia and lymphoproliferative disorders should shed light on this important question.
